Author:
Landgren O,Devlin S,Boulad M,Mailankody S
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference30 articles.
1. Kristinsson SY, Anderson WF, Landgren O . Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia 2014; 28: 1346–1348.
2. US Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. 2016 Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm .
3. Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 2015; 12: 286–295.
4. Gormley NJ, Turley DM, Dickey JS, Farrell AT, Reaman GH, Stafford E et al. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma. Cytometry B Clin Cytom 2016; 90: 73–80.
5. Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol 2015; 1: 746–754.
Cited by
164 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献